• Omni

  Participated · Equity · Jun 2026

  Omni develops a range of plant-based, vet-formulated dog foods, treats, supplements, dental sticks, shampoos and calming products using novel proteins from yeast, algae and pulses. The company sells dry foods and wet-style meals, training treats, and a portfolio of supplements addressing skin, breath, gut health and weight management. Omni is commercial and growing quickly—founders Guy Sandelowsky and Shiv Sivakumar say annualised sales rose from about £1M to close to £13M and the brand has helped more than 300,000 dogs, with a 130% sales lift and 20,000 new customers after its Dragons’ Den appearance. It is developing LeanPaws, an Ozempic-style weight-loss supplement for dogs; a placebo-controlled trial reported 77% of overweight dogs taking LeanPaws lost some weight, 63% reduced body fat composition, and 42% showed fewer begging behaviors with virtually no side effects. Omni highlights the lower carbon footprint of its recipes—about 73% fewer emissions than standard meat-based dog food—and cites avoided customer CO2e contributions over time. The company plans to use new funding to scale UK retail presence, enter the US market, continue clinical research, and expand the team.

• Travv

  Participated · Seed · May 2026

  Travv offers an AI-native, cloud-based diagnostic platform for veterinary medicine that integrates RIS, PACS, and LIS capabilities into a single system. The platform supports a growing suite of traditional and emerging diagnostic services for veterinary hospitals and providers. Led by founder and CEO Derick Whitley, DVM, DACVP, the company is headquartered in Stillwater, OK. Travv closed a $1.6M seed round to fund continued product development, hospital onboarding, commercial growth, and key integrations. The financing was led by Digitalis Ventures with participation from AniVC. No revenue, user metrics, prior funding rounds, or valuation were disclosed in the announcement.

No current team members are available.